Effectiveness, safety for bone marrow protection of trilaciclib for patients with locally advanced carcinoma: A real-word evidence analysis.

Abstract

e15109 Background: Trilaciclib as the selective and reversible CDK4/6 inhibitor was approved for use in patients with extensive stage small cell lung cancer who treated with a platinum-containing agent in combination with an etoposide regimen, to reduce the incidence of chemotherapy-induced myelosuppression. But there are limited data regarding the safety and efficacy of Trilaciclib for different kinds of tumors. Methods: The first affiliated hospital of Xinxiang Medical University took the lead in conducting this multicenter, single-arm, non-interventional, real-world study in order to explore the myeloprotective effect of Trilaciclib preventive use on malignant patients in China in a real-world setting and to evaluate the safety of its combination with chemotherapy regimen. Baseline demographics, disease characteristics, Blood routine, toxicity, and time of administration were abstracted from the electronic medical record. Results: 40 patients treated with chemotherapy who received Trilaciclib were included (2 with breast Cancer, 8 with Small Cell Lung Cancers, 7 with Non-Small Cell Lung Cancers, 5 with Esophageal Cancer, 8 with Gynecological Tumors, 4 with Gastrointestinal Tumors and 6 with others carcinomas). The median age is 62.92±9.78. Trilaciclib therapy reduced the incidence of CRA by 5% and CIM by 12.5%, respectively. In addition, there was a 5% decrease in the incidence of III-IV grade CIT (3/40-1/40). Efficacy results are summarized(Table). Chemotherapy with Trilaciclib significantly preserved the hematological function in two patients with II grade CIT (70 to 74, 55 to 108). Furthermore, 12 instances of prolonged administration lasting more than five days occurred in chemotherapy cycles without Trilaciclib, and 6 of these cases had prolonged administration lasting longer than five days followed by Trilaciclib use. Conclusions: Trilaciclib is an effective treatment option for patients with potential CIM under the treatment of chemotherapy. Trilaciclib may play a more essential role in this subset of patients who do not recover quickly from chemotherapy-induced platelet decreases in order to take their medication on time, as well as in terms of bone marrow protection and safety, although more clinical data are needed to support this. CIN BP(%) AP(%) CIT BP(%) AP(%) CRA BP(%) AP(%) I-II 55 60 I-II 72.5 90 I-II 45 37.5 III-IV 40 22.5 III-IV 7.5 2.5 III-IV 7.5 10 ALL 95 82.5 ALL 80 92.5 ALL 52.5 47.5 CIM: Chemotherapy-induced myelosuppression; CIN: Chemotherapy induced neutropenia; CIT: Chemotherapy induced thrombocytopenia; CRA: Ccancer related anemia; BP: Before prevention of Trilaciclib; AP: After prevention of Trilaciclib.